Stock

Spherix Announces a Special Dividend Distribution

Corporate finance, Equity securities, Financial economics, Finance, Money, Stock market, Common stock, Stock
Sunday, February 23, 2020 - 3:00pm

NEW YORK, Feb. 23, 2020 /PRNewswire/ --Spherix Incorporated (Nasdaq: SPEX) today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix.

Key Points: 
  • NEW YORK, Feb. 23, 2020 /PRNewswire/ --Spherix Incorporated (Nasdaq: SPEX) today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix.
  • Spherix will not distribute fractional shares of Hoth common stock, and any fractional shares will be rounded down to the nearest whole share.
  • Spherix stockholders do not need to take any action to receive the shares of Hoth common stock, other than be a shareholder of record on March 4, 2020.
  • Spherix stockholders do not need to pay any consideration for, surrender or exchange shares of Spherix common stock.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation on the Following Mergers

Finance, Financial markets, Money, Stock market, Legal entities, Corporate finance, Law firm, Practice of law, Morgan Stanley, Security, Stock, Short
Saturday, February 22, 2020 - 1:00am

Click here for more information: https://www.monteverdelaw.com/case/adesto-technologies-corporation .It is free and there is no cost or obligation to you.

Key Points: 
  • Click here for more information: https://www.monteverdelaw.com/case/adesto-technologies-corporation .It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, E*TRADE stockholders will receive 1.0432 Morgan Stanley shares for each E*TRADE share owned.
  • Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.
  • Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Jernigan Capital Announces Dividends for First Quarter 2020

Professional services, Other Construction & Property, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Financial markets, Financial economics, Equity securities, Corporate finance, Stock market, Dividends, Shareholders, Preferred stock, Common stock, Stock
Friday, February 21, 2020 - 10:21pm

Jernigan Capital, Inc. (NYSE:JCAP) (the Company) announced today that its Board of Directors declared a cash dividend of $0.23 per share of common stock for the quarter ending March 31, 2020.

Key Points: 
  • Jernigan Capital, Inc. (NYSE:JCAP) (the Company) announced today that its Board of Directors declared a cash dividend of $0.23 per share of common stock for the quarter ending March 31, 2020.
  • The dividend is payable on April 15, 2020 to stockholders of record on April 1, 2020.
  • The Companys Board of Directors also declared a cash dividend on the Series B Preferred Stock in the amount of $0.4375 per share for the quarter ending March 31, 2020.
  • The dividend is payable on April 15, 2020 to holders of Series B Preferred Stock of record on April 1, 2020.

Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Financial markets, Finance, Economy, Corporate finance, Stock market, Employee stock ownership, Fundamental analysis, Restricted stock, NASDAQ, Stock, Option, Short
Friday, February 21, 2020 - 9:15pm

The stock options are exercisable at a price of$23.94 per share, the closing price of Intra-Cellular Therapies common stock onFebruary 18, 2020, the grant date.

Key Points: 
  • The stock options are exercisable at a price of$23.94 per share, the closing price of Intra-Cellular Therapies common stock onFebruary 18, 2020, the grant date.
  • The stock options and restricted stock units were granted as inducements material to each employees acceptance of employment with Intra-Cellular Therapies in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options and restricted stock units are subject to the terms and conditions of Intra-Cellular Therapies 2019 Inducement Award Plan, and the terms and conditions of equity award agreements covering the grants.
  • Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body.

Hecla Declares Common and Preferred Dividends

Mining, Minerals, Natural Resources, Financial markets, Financial economics, Corporate finance, Stock market, Equity securities, Dividends, Shareholders, Preferred stock, Share, Stock, Common stock, Dividend yield
Friday, February 21, 2020 - 9:50pm

Hecla Mining Company ( NYSE:HL ) today announced its Board of Directors declared a quarterly dividend of $0.0025 per share of common stock, payable on or about March 13, 2020, to shareholders of record on March 6, 2020.

Key Points: 
  • Hecla Mining Company ( NYSE:HL ) today announced its Board of Directors declared a quarterly dividend of $0.0025 per share of common stock, payable on or about March 13, 2020, to shareholders of record on March 6, 2020.
  • The Board of Directors also declared the regular quarterly dividend of $0.875 per share on the 157,816 shares of outstanding Series B Cumulative Convertible Preferred Stock.
  • The cash dividend is payable April 1, 2020, to shareholders of record on March 13, 2020.
  • The Company undertakes no obligation and has no intention of updating forward-looking statements other than as may be required by law.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Canaan Inc. (CAN) on Behalf of Investors

Legal, Professional services, Financial markets, Finance, Financial economics, Initial public offering, Corporate finance, Equity securities, Stock market, Depositary receipts, American depositary receipt, Security, Public offering, Stock
Friday, February 21, 2020 - 7:56pm

Law Offices of Howard G. Smith announces an investigation on behalf Canaan Inc. (Canaan or the Company) (NASDAQ: CAN ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf Canaan Inc. (Canaan or the Company) (NASDAQ: CAN ) investors concerning the Company and its officers possible violations of federal securities laws.
  • In November 2019, Canaan completed its initial public offering (IPO), issuing 10 million American Depositary Shares (ADSs), at $9.00 per share.
  • Since the IPO, Canaans stock has traded as low as $5.72 per share, significantly below the $9 offering price.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Robbins LLP Is Investigating the Former Officers and Directors of Liberty Expedia Holdings, Inc. (LEXEA, LEXEB) on Behalf of Former Shareholders

Legal, Professional services, Stock market, Finance, Financial economics, Money, Corporate finance, Stock, Security, Securities Class Action
Friday, February 21, 2020 - 4:13pm

Robbins LLP is a nationally recognized leader in shareholder rights law.

Key Points: 
  • Robbins LLP is a nationally recognized leader in shareholder rights law.
  • The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
  • Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.
  • Past results do not guarantee a similar outcome.

Universal Technical Institute Prices Upsized Offering of 6,782,610 Shares of Common Stock

Financial markets, Finance, Financial economics, Initial public offering, Corporate finance, Stock market, Automotive industry in the United States, Universal Technical Institute, Underwriting, UTI, Stock, Public offering
Friday, February 21, 2020 - 2:00pm

SCOTTSDALE, Ariz., Feb. 21, 2020 /PRNewswire/ --Universal Technical Institute, Inc. (NYSE: UTI), the leading provider of transportation technician training, announced today the pricing of an underwritten public offering of 6,782,610 shares of its common stock at a public offering price of$7.75per share, before underwriting discounts and commissions.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 21, 2020 /PRNewswire/ --Universal Technical Institute, Inc. (NYSE: UTI), the leading provider of transportation technician training, announced today the pricing of an underwritten public offering of 6,782,610 shares of its common stock at a public offering price of$7.75per share, before underwriting discounts and commissions.
  • The size of the offering was increased from the previously announced 5,650,000 shares of common stock.
  • In addition, Universal Technical Institute has granted the underwriters a 30-day option to purchase up to 1,017,390 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares are to be sold by Universal Technical Institute.

Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering

Finance, Money, Corporate finance, Financial economics, Equity securities, Stock market, Initial public offering, Prospectus, Private placement, Stock, Placement, Warrant
Friday, February 21, 2020 - 2:15pm

In a concurrent private placement, Adamis has agreed to issue warrants to purchase up to an aggregate of 8,700,000 shares of common stock.

Key Points: 
  • In a concurrent private placement, Adamis has agreed to issue warrants to purchase up to an aggregate of 8,700,000 shares of common stock.
  • The gross proceeds to the Company from the registered direct offering and concurrent private placement are expected to be approximately $6.7 million before deducting the placement agents fees and other estimated offering expenses.
  • The registered direct offering and concurrent private placement is expected to close on or about February 25, 2020, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement relating to the shares of common stock will be filed by Adamis Pharmaceuticals with the SEC.

EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Financial markets, Finance, Financial economics, Corporate finance, Initial public offering, Stock market, Underwriting, Public offering, Stock
Friday, February 21, 2020 - 2:09pm

WATERTOWN, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share.

Key Points: 
  • WATERTOWN, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share.
  • The gross proceeds of the offering to the Company are expected to be approximately $21,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses.
  • In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The closing of the offering is expected to occur on or about February 25, 2020, subject to the satisfaction of customary closing conditions.